Sep 17, 08
|
| NEW STORY |
| 16:00 ET |
Medarex to Present at the UBS Global Life Sciences Conference
|
|
Sep 08, 08
|
| 08:00 ET |
Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
|
|
Sep 04, 08
|
| 08:00 ET |
Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
|
|
Sep 02, 08
|
| 16:00 ET |
Medarex to Present at the Thomas Weisel Partners Healthcare Conference
|
|
Aug 12, 08
|
| 10:00 ET |
Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
|
|
Aug 05, 08
|
| 16:09 ET |
Medarex Announces 2008 Second Quarter Financial Results
|
|
| 08:00 ET |
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
|
|
Jul 23, 08
|
| 08:00 ET |
Medarex Receives Milestone Payment for Acceptance of Investigational New Drug Application
|
|
Jul 16, 08
|
| 06:00 ET |
BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology
|
|
Jul 10, 08
|
| 15:54 ET |
Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
|
|
Jul 07, 08
|
| 12:26 ET |
Medarex Announces July 10 Live Webcast of R&D Day Event
|
|
Jun 18, 08
|
| 07:00 ET |
Medarex to Present at the Jefferies Second Annual Healthcare Conference
|
|
Jun 03, 08
|
| 07:00 ET |
Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
|
|
Jun 02, 08
|
| 12:30 ET |
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
|
|
| 06:30 ET |
Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
|
|
Jun 01, 08
|
| 15:15 ET |
Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
|
|
May 30, 08
|
| 08:00 ET |
Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
|
|
May 21, 08
|
| 08:00 ET |
Medarex Reports Phase 1 Clinical Data of MDX-1100 at Digestive Disease Week
|
|
May 16, 08
|
| 08:00 ET |
Medarex Announces June 2nd Webcast Review and Discussion of Ipilimumab Data Presented at ASCO
|
|
May 12, 08
|
| 08:00 ET |
Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
|
|
| 07:00 ET |
Medarex Announces 2008 First Quarter Financial Results
|
|
May 06, 08
|
| 07:00 ET |
Medarex to Present at the Bank of America 2008 Healthcare Conference
|
|
Apr 29, 08
|
| 08:00 ET |
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
|
|
Apr 25, 08
|
| 16:10 ET |
Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
|
|
Apr 22, 08
|
| 07:00 ET |
Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
|
|
Apr 16, 08
|
| 16:00 ET |
Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
|
|
| 08:00 ET |
Medarex Reports Preclinical Data on Multiple Antibody-Drug Conjugate Candidates at American Association for Cancer Research Meeting
|
|
Apr 15, 08
|
| 11:00 ET |
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
|
|
Apr 03, 08
|
| 08:00 ET |
Medarex Announces Ipilimumab Program Continues to Move Forward
|
|
Mar 31, 08
|
| 06:00 ET |
Medarex to Receive Milestone Payment from Novo Nordisk
|
|
Mar 20, 08
|
| 10:32 ET |
Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
|
|
Mar 17, 08
|
| 07:00 ET |
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
|
|
Feb 28, 08
|
| 16:00 ET |
Medarex to Present at the Susquehanna Financial Group Healthcare Conference
|
|
Feb 26, 08
|
| 16:00 ET |
Medarex Announces 2007 Fourth Quarter and Year End Financial Results
|
|
Feb 20, 08
|
| 16:09 ET |
Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
|
|
Feb 01, 08
|
| 06:00 ET |
Medarex Announces Completion of Sale of Shares in Genmab A/S
|
|
Jan 31, 08
|
| 16:00 ET |
Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
|
|
Jan 24, 08
|
| 07:00 ET |
Medarex to Present at the 2008 Wachovia Healthcare Conference
|
|
Jan 08, 08
|
| 07:00 ET |
Medarex Announces Allowance of Investigational New Drug Application for Wholly Owned Fully Human Anti-CD70 Antibody, MDX-1411
|
|
| 06:00 ET |
PharmAthene and Medarex Announce FY 2008 U.S. Congressional Appropriation of up to $1.6 Million for Continued Development of Anthrax Therapeutic Valortim(TM)
|
|
Jan 03, 08
|
| 07:00 ET |
Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
|
|
Dec 18, 07
|
| 06:00 ET |
Medarex to Receive Milestone Payment from Amgen
|
|
Dec 07, 07
|
| 06:00 ET |
Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
|
|
Dec 04, 07
|
| 06:00 ET |
Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
|
|
Nov 08, 07
|
| 07:00 ET |
Medarex Announces Presentations on UltiMAb(R) Antibodies at 71st Annual Meeting of the American College of Rheumatology
|
|
Nov 07, 07
|
| 16:00 ET |
Medarex Announces Election of Marc Rubin as New Board Member
|
|
Oct 31, 07
|
| 16:00 ET |
Medarex Announces 2007 Third Quarter Financial Results
|
|
Oct 30, 07
|
| 07:00 ET |
Medarex to Present at the JPMorgan Small/Mid Cap Conference
|
|
Oct 29, 07
|
| 16:00 ET |
Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
|
|
Oct 17, 07
|
| 07:00 ET |
Medarex Announces the Appointment of Ursula B. Bartels as Senior Vice President, General Counsel and Secretary
|
|
Oct 01, 07
|
| 06:00 ET |
Medarex to Present at the Natixis Bleichroeder's Hidden Gems Conference
|
|
Sep 26, 07
|
| 16:00 ET |
PharmAthene Awarded Up to $13.9 Million NIH Contract to Develop Anthrax Anti-Toxin, Valortim(TM) with Medarex
|
|
Sep 19, 07
|
| 06:00 ET |
Medarex to Present at the UBS Global Life Sciences Conference
|
|
Sep 12, 07
|
| 16:00 ET |
Medarex to Present at the A.G. Edwards' 2nd Annual Emerging Growth Conference
|
|
Sep 05, 07
|
| 06:00 ET |
Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
|
|
Sep 04, 07
|
| 06:00 ET |
Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
|
|
Aug 30, 07
|
| 06:00 ET |
Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
|
|
Jul 31, 07
|
| 07:00 ET |
Medarex Announces 2007 Second Quarter Financial Results
|
|
| 06:00 ET |
Preliminary Data Add New Mechanistic Insights to Activity of Anthrax Anti-Toxin, Valortim(TM)
|
|
Jul 19, 07
|
| 14:05 ET |
Medarex Announces Advancement of Antibody Development by Partner
|
|
Jul 18, 07
|
| 06:00 ET |
Medarex Announces Initiation by Licensing Partner of Phase III Clinical Trial for Muckle Wells Syndrome
|
|
Jun 14, 07
|
| 16:00 ET |
Medarex to Present at NASDAQ's 19th Investor Program Healthcare Forum
|
|
Jun 07, 07
|
| 07:00 ET |
Medarex to Present at the Sixth Annual Needham Biotechnology and Medical Technology Conference
|
|
Jun 06, 07
|
| 07:00 ET |
Medarex to Present at the 28th Annual Goldman Sachs Global Healthcare Conference
|
|
May 31, 07
|
| 06:00 ET |
Medarex Announces Collaborative Research Agreement with Mitsubishi Pharma
|
|
May 30, 07
|
| 06:00 ET |
Medarex to Present at the Bear Stearns Biotech Confab
|
|
May 24, 07
|
| 06:00 ET |
Medarex to Present at the Bank of America 2007 Health Care Conference
|
|
May 16, 07
|
| 16:00 ET |
Medarex Announces the Appointment of Mr. Howard H. Pien as President and Chief Executive Officer and Member of the Medarex Board of Directors
|
|
| 08:00 ET |
Medarex and Organon Announce Biotherapeutics Development Agreement
|
|
| 06:00 ET |
Medarex to Present at the Citigroup Global Healthcare Conference
|
|
May 03, 07
|
| 06:00 ET |
Medarex to Receive Milestone Payment from Amgen
|
|
May 01, 07
|
| 16:26 ET |
Medarex Announces 2007 First Quarter Financial Results
|
|
Apr 26, 07
|
| 07:00 ET |
Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
|
|
Apr 17, 07
|
| 08:32 ET |
Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models
|
|
Mar 29, 07
|
| 07:00 ET |
Anthrax Monoclonal Antibody Valortim(TM) Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection
|
|
Mar 23, 07
|
| 12:17 ET |
Medarex Announces Initiation of Phase I Clinical Trial for the Treatment of Psoriasis
|
|
Feb 28, 07
|
| 16:00 ET |
Medarex Announces 2006 Fourth Quarter and Year End Financial Results
|
|
Feb 23, 07
|
| 06:00 ET |
Medarex to Announce 2006 Fourth Quarter and Year-End Financial Results on February 28, 2007
|
|
Feb 22, 07
|
| 07:00 ET |
Cell Genesys and Medarex Announce Encouraging Follow-Up Results from a Phase 1 Combination Therapy Trial With GVAX(TM) Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody
|
|
Feb 20, 07
|
| 07:00 ET |
Medarex Announces Sale of Shares in Genmab A/S
|
|
Feb 07, 07
|
| 06:00 ET |
Medarex to Present at the BIO CEO and Investor Conference
|
|
Jan 23, 07
|
| 06:00 ET |
Medarex and Compugen Announce Therapeutic Antibody Co-Development Agreement
|
|
Jan 09, 07
|
| 06:00 ET |
BioWa and Medarex Announce Allowance of Investigational New Drug Application for Second-Generation Anti-CD30 Antibody (MDX-1401) Enhanced Using Potelligent(TM) Technology
|
|
Jan 04, 07
|
| 07:00 ET |
Medarex Announces Enrollment Complete in Ipilimumab (MDX-010) Monotherapy Pivotal Registrational Trial for Metastatic Melanoma
|
|
Jan 03, 07
|
| 16:00 ET |
Medarex Announces Clinical Development Milestone Achieved by ImClone Systems for Fully Human Antibody for the Treatment of Cancer
|
|
Jan 02, 07
|
| 16:00 ET |
Medarex to Present at the 25th Annual JPMorgan Healthcare Conference
|
|
Dec 11, 06
|
| 16:12 ET |
Ipilimumab (MDX-010) Safety and Clinical Response Data in Lymphomas and Leukemia Presented at the 48th American Society of Hematology Annual Meeting
|
|
Dec 07, 06
|
| 06:00 ET |
Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma; Fast Track Designations for First-Line Use in Combination With Chemotherapy and Second-Line Use as Monotherapy
|
|
Nov 30, 06
|
| 06:00 ET |
Medarex to Present at NASDAQ's 18th Investor Program
|
|
Nov 17, 06
|
| 16:00 ET |
Medarex Receives NASDAQ Notice Regarding Delayed Filing of Form 10-Q
|
|
Nov 13, 06
|
| 06:00 ET |
Medarex to Receive Milestone Payment from Amgen
|
|
Nov 09, 06
|
| 06:00 ET |
Medarex to Present at the Credit Suisse Health Care Conference
|
|
Nov 07, 06
|
| 16:00 ET |
Medarex to Present at the JPMorgan Small/Mid Cap Boston Conference
|
|
| 06:00 ET |
Medarex and PacMab Announce Therapeutic Antibody Co-Development Agreement
|
|
Nov 06, 06
|
| 08:35 ET |
Medarex Announces Board and Management Changes and Results of Previously Announced Internal Investigation
|
|
Oct 24, 06
|
| 06:00 ET |
Medarex to Present at the C.E. Unterberg, Towbin Life Sciences Conference
|
|
Oct 16, 06
|
| 06:00 ET |
Medarex and PharmAthene Announce Phase I Results of Anthrax Therapeutic Valortim(TM)
|
|
Oct 11, 06
|
| 06:00 ET |
PharmAthene and Medarex Announce $1 Million Congressional Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
|
|
Oct 04, 06
|
| 19:30 ET |
Medarex Amends Indenture Governing 2.25% Convertible Senior Notes due 2011 and Announces Close of Consent Solicitation
|
|
Oct 02, 06
|
| 20:30 ET |
Medarex Announces Changes in Terms of 2.25% Convertible Senior Notes Consent Solicitations
|
|
Sep 22, 06
|
| 07:00 ET |
Medarex Announces Commencement of Consent Solicitation for 2.25% Convertible Senior Notes due 2011
|
|
Sep 18, 06
|
| 06:00 ET |
Medarex to Present at the UBS Global Life Sciences Conference
|
|
Sep 15, 06
|
| 16:09 ET |
Medarex Announces Election of Two New Board Members
|
|
Sep 06, 06
|
| 06:00 ET |
Medarex and Massachusetts Biologic Laboratories Announce Commencement of Phase II Clinical Trial of Anti-C. difficile Antibody Combination for the Treatment of Hospital Acquired Diarrhea
|
|
Sep 05, 06
|
| 06:00 ET |
Medarex to Present at the Bear Stearns 19th Annual Healthcare Conference
|
|
Aug 31, 06
|
| 16:13 ET |
Medarex Announces Receipt of Notice of Default Relating to Medarex's 2.25% Convertible Senior Notes Due May 15, 2011
|
|
Aug 28, 06
|
| 06:00 ET |
Medarex to Present at the BioCentury and Thomson Financial NewsMakers in the Biotech Industry Conference
|
|
Aug 24, 06
|
| 06:00 ET |
Medarex to Present at the Thomas Weisel Partners Annual Healthcare Conference
|
|
Aug 22, 06
|
| 06:00 ET |
Medarex and GenPat77 Announce Therapeutic Antibody Co-Development Agreement
|
|
Aug 18, 06
|
| 16:11 ET |
Medarex Announces Expected Restatement of Previously Issued Financial Statements; Receives Nasdaq Notice Regarding Delayed Filing of Form 10-Q
|
|
Aug 01, 06
|
| 07:00 ET |
Ono and Medarex Announce Allowance of Investigational New Drug Application for MDX-1106 for the Treatment of Cancer
|
|
Jun 26, 06
|
| 06:00 ET |
Euroscreen and Medarex Announce License and Research Service Agreement
|
|
Jun 22, 06
|
| 07:00 ET |
Celera Genomics and Medarex Establish Therapeutic Antibody Collaboration in Cancer
|
|
Jun 19, 06
|
| 07:30 ET |
Medarex Announces Special Protocol Assessment Agreement With the FDA to Initiate Registrational Trial for Ipilimumab (MDX-010) Combination With Chemotherapy in First-Line Metastatic Melanoma Patients
|
|
Jun 08, 06
|
| 07:00 ET |
Medarex to Present at the Fifth Annual Needham Biotechnology and Medical Technology Conference
|
|
Jun 06, 06
|
| 07:00 ET |
Medarex to Present at the 27th Annual Goldman Sachs Global Healthcare Conference
|
|
Jun 05, 06
|
| 08:00 ET |
Interim Ipilimumab (MDX-010) Phase II Trial Results Indicate Well-Tolerated, Extended Dosing with Preliminary Evidence that Immune Activation May Reduce Relapse in the Adjuvant Setting in Melanoma
|
|
| 07:30 ET |
Ipilimumab (MDX-010) Shows Encouraging Data in Phase I and Phase II Clinical Trials for Hormone Refractory Prostate Cancer Patients
|
|
Jun 03, 06
|
| 08:02 ET |
Medarex and Cell Genesys Announce Encouraging Interim Results from a Phase I Combination Therapy Trial with GVAX(R) Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody
|
|
May 24, 06
|
| 16:00 ET |
Medarex to Present at the Bear Stearns Biotech Boston Confab
|
|
May 10, 06
|
| 05:00 ET |
Oxford Genome Sciences and Medarex Sign Therapeutic Antibody Collaboration Agreement in Cancer
|
|
May 09, 06
|
| 06:00 ET |
Medarex to Present at the Bank of America Health Care Conference 2006
|
|
May 08, 06
|
| 16:00 ET |
Medarex Announces Exercise of Option to Purchase Additional Shares by Underwriters
|
|
May 05, 06
|
| 07:00 ET |
Medarex Announces 2006 First Quarter Financial Results
|
|
Apr 26, 06
|
| 06:00 ET |
Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
|
|
Apr 13, 06
|
| 14:02 ET |
Medarex Announces Start of Dosing in Phase I Clinical Trial for the Treatment of Lupus
|
|
Apr 07, 06
|
| 10:56 ET |
Medarex Announces Pricing of Public Offering of Common Stock
|
|
Apr 03, 06
|
| 07:15 ET |
Medarex Announces Public Offering of Common Stock
|
|
Mar 31, 06
|
| 07:00 ET |
Medarex Announces Initiation of Registrational Trial for Ipilimumab (MDX-010) as Monotherapy in Previously-Treated Metastatic Melanoma Patients
|
|
Mar 28, 06
|
| 06:00 ET |
Ono and Medarex Enter Into Second Collaboration for the Development of a Fully Human Antibody Therapeutic
|
|
Mar 13, 06
|
| 10:52 ET |
Data from Ipilimumab / GVAX(R) Prostate Combination Trial Expected at Upcoming 2006 ASCO Annual Meeting
|
|
Mar 06, 06
|
| 16:08 ET |
Medarex Announces 2005 Fourth Quarter and Year End Financial Results
|
|
| 06:00 ET |
PharmAthene and Medarex Receive Orphan Drug Designation for Valortim(TM) to Treat Anthrax Infection
|
|
Mar 02, 06
|
| 12:30 ET |
Medarex to Announce 2005 Fourth Quarter and Year-End Financial Results on March 6, 2006
|
|
Feb 23, 06
|
| 06:04 ET |
Medarex Announces New Presentation Time at Citigroup 2006 Healthcare Conference
|
|
Feb 22, 06
|
| 06:00 ET |
Medarex to Present at the Citigroup 2006 Healthcare Conference
|
|
Feb 09, 06
|
| 16:00 ET |
Medarex to Present at the BIO CEO and Investor Conference
|
|
Feb 01, 06
|
| 06:00 ET |
Medarex and Organon Announce Antibody Development Agreement
|
|
Jan 30, 06
|
| 06:00 ET |
Medarex Receives Milestone Payment From ImClone Systems Following Acceptance of Investigational New Drug Application for Fully Human Antibody
|
|
Jan 19, 06
|
| 06:00 ET |
Medarex Announces NovImmune Filing of Investigational New Drug Application for Fully Human Antibody for the Treatment of Autoimmune Disease
|
|
Jan 10, 06
|
| 06:00 ET |
PharmAthene and Medarex Receive $2.05 Million Congressional Appropriation for Continued Development of Valortim(TM) for Prevention and Treatment of Anthrax Infection
|
|
Jan 09, 06
|
| 06:00 ET |
PharmAthene and Medarex Receive FDA Fast Track Designation for Valortim(TM) for Treatment of Anthrax Infection
|
|
Jan 04, 06
|
| 06:00 ET |
Medarex to Present at the 24th Annual JPMorgan Healthcare Conference
|
|
Dec 13, 05
|
| 17:11 ET |
Twenty-Seventh UltiMAb(R) Antibody Enters Clinical Development
|
|
Dec 05, 05
|
| 16:00 ET |
Medarex to Present at NASDAQ's 16th Investor Program
|
|
| 06:00 ET |
Medarex Announces Webcast of 2005 R&D Day Presentations on December 9, 2005
|
|
Nov 15, 05
|
| 06:00 ET |
Medarex Announces Clinical Development Milestone Achieved by Bristol-Myers Squibb for Therapeutic Antibody Targeting Cancer
|
|
Nov 09, 05
|
| 06:00 ET |
Medarex to Present at the CSFB Healthcare Conference
|
|
Nov 04, 05
|
| 08:03 ET |
Medarex Announces 2005 Third Quarter Financial Results
|
|
Nov 01, 05
|
| 06:00 ET |
Medarex to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference
|
|
Oct 18, 05
|
| 06:02 ET |
Medarex to Present at the C.E. Unterberg, Towbin Life Sciences Conference
|
|
Oct 11, 05
|
| 08:00 ET |
Medarex and Massachusetts Biologic Laboratories Announce Commencement of Phase II Clinical Trial of a Fully Human Antibody for the Treatment of Hospital Acquired Diarrhea
|
|
| 07:00 ET |
Fully Human Anti-Anthrax Antibody Enlists Immune System to Neutralize Anthrax Toxin in Preclinical Studies
|
|
Sep 21, 05
|
| 14:11 ET |
Medarex to Showcase Proprietary Ultra-Potent Toxin(TM) Conjugate Technology in Webcast Discussion on September 27, 2005
|
|
Sep 20, 05
|
| 16:30 ET |
Medarex to Present at the UBS Global Life Sciences Conference
|
|
Sep 12, 05
|
| 06:00 ET |
Medarex Announces Agreement to License UltiMAb Human Antibody Development System(R) to ImClone Systems
|
|
Sep 08, 05
|
| 06:00 ET |
Medarex to Present at the ThinkEquity Partners Third Annual Growth Conference
|
|
Sep 07, 05
|
| 06:00 ET |
Medarex to Present at the Bear Stearns 18th Annual Healthcare Conference
|
|
Aug 08, 05
|
| 12:14 ET |
Medarex and PharmAthene Announce Phase I Clinical Trial of Valortim(TM); Fully Human Anti-Anthrax Antibody to Begin Clinical Trial
|
|
Aug 04, 05
|
| 16:11 ET |
Medarex Announces 2005 Second Quarter Financial Results
|
|
Jun 24, 05
|
| 12:13 ET |
Medarex President and CEO Receives Ernst & Young Entrepreneur Of The Year(R) 2005 Award
|
|
Jun 20, 05
|
| 18:00 ET |
Medarex Post-Effective Amendments Become Effective
|
|
Jun 14, 05
|
| 06:00 ET |
Medarex and Boehringer Ingelheim Announce Antibody Development Agreement
|
|
Jun 13, 05
|
| 06:00 ET |
Medarex to Present at the 25th Annual William Blair & Company Growth Stock Conference
|
|
Jun 10, 05
|
| 17:06 ET |
Medarex Files Post-Effective Amendments with SEC
|
|
Jun 06, 05
|
| 06:00 ET |
Medarex to Present at the 26th Annual Goldman Sachs Global Healthcare Conference
|
|
Jun 03, 05
|
| 17:02 ET |
Medarex Files Post-Effective Amendments with SEC
|
|
May 26, 05
|
| 06:00 ET |
Medarex to Present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference
|
|
May 24, 05
|
| 06:00 ET |
BioWa and Medarex Announce Expansion of Licensing Agreement for BioWa's Potelligent(TM) Technology
|
|
May 19, 05
|
| 16:00 ET |
Medarex to Present at the Fourth Annual Needham Biotechnology Conference
|
|
May 13, 05
|
| 16:30 ET |
Medarex to Present at the Banc of America Securities Health Care Conference 2005
|
|
May 12, 05
|
| 16:00 ET |
Medarex Announces Webcast Discussion of 2005 ASCO Data and Recent Product Development Programs
|
|
| 08:01 ET |
Ono and Medarex Enter Into Collaborative Research Agreement on Antibody Product
|
|
May 11, 05
|
| 06:01 ET |
Medarex Announces Phase I Clinical Trial of MDX-1100, a Fully Human Anti-IP10 Antibody, for the Treatment of Ulcerative Colitis
|
|
May 09, 05
|
| 16:02 ET |
Medarex Announces 2005 First Quarter Financial Results
|
|
| 06:00 ET |
Medarex Announces Upcoming Presentations at American Society of Clinical Oncology Meeting
|
|
May 02, 05
|
| 06:00 ET |
Medarex to Announce First Quarter Results on May 9, 2005
|
|
Apr 20, 05
|
| 16:00 ET |
Phase II Clinical Study of MDX-010/MDX-1379 Combination Shows Durable Responses in Patients with Metastatic Melanoma
|
|
Apr 14, 05
|
| 06:00 ET |
Medarex Announces Upcoming Presentations at American Association for Cancer Research Meeting
|
|
Apr 01, 05
|
| 06:00 ET |
Cytos Biotechnology and Medarex Expand Their Collaboration for New Drug Targets
|
|
Mar 07, 05
|
| 06:01 ET |
Medarex and Bristol-Myers Squibb Announce Complete and Partial Responses Observed in Phase I/II Clinical Study of MDX-010 in Combination with Il-2
|
|
Feb 28, 05
|
| 16:01 ET |
Medarex Announces 2004 Fourth Quarter and Year End Financial Results
|
|
Feb 24, 05
|
| 14:46 ET |
Medarex Awarded Esteemed Biotechnology Industry Award
|
|
| 06:01 ET |
Medarex to Receive Milestone Payment from Amgen; 22nd UltiMAb(R) Product to Enter Clinical Trials
|
|
Feb 23, 05
|
| 06:00 ET |
Medarex to Present at the Wells Fargo Securities 2005 Healthcare Conference
|
|
Feb 22, 05
|
| 16:03 ET |
Medarex to Announce 2004 Fourth Quarter and Year-End Financial Results on February 28, 2005
|
|
Feb 17, 05
|
| 06:01 ET |
Medarex to Present at the 7th Annual BIO CEO and Investor Conference
|
|
Jan 14, 05
|
| 06:00 ET |
Medarex Announces Completion of Redemption of 4.25% Convertible Senior Notes Due August 15, 2010
|
|
Jan 13, 05
|
| 06:00 ET |
Bristol-Myers Squibb and Medarex Global Development and Commercialization Collaboration for MDX-010 Becomes Effective
|
|
Jan 06, 05
|
| 06:01 ET |
Medarex to Present at the 23rd Annual JPMorgan Healthcare Conference
|
|
Dec 21, 04
|
| 06:03 ET |
Genmab A/S and Medarex Announce Positive Safety and Efficacy Data in Phase I/II Trial with HuMax-Inflam/MDX-018
|
|
Dec 15, 04
|
| 08:02 ET |
Medarex Announces Redemption of 4.25% Convertible Senior Notes Due August 15, 2010
|
|
Dec 10, 04
|
| 06:00 ET |
Bristol-Myers Squibb and Medarex Provide Additional Information to FTC
|
|
Dec 06, 04
|
| 08:02 ET |
Medarex Announces Complete and Partial Responses Observed in Clinical Study of MDX-060 at ASH Meeting
|
|
| 06:00 ET |
Anti-Anthrax Antibody Subject of Collaboration
|
|
Nov 29, 04
|
| 06:00 ET |
Medarex to Receive Milestone Payment from Amgen; 21st UltiMAb(R) Product to Enter Clinical Trials
|
|
Nov 23, 04
|
| 08:30 ET |
Medarex to Host Conference Call Today to Discuss MedImmune Development and Commercialization Collaboration for Fully Human Antibodies for Autoimmune Diseases
|
|
| 08:00 ET |
MedImmune and Medarex Announce Collaboration to Develop and Commercialize Fully Human Antibodies for Autoimmune Diseases
|
|
Nov 15, 04
|
| 06:00 ET |
Medarex to Present at the CSFB Healthcare Conference
|
|
Nov 08, 04
|
| 08:05 ET |
Medarex Announces 2004 Third Quarter Financial Results
|
|
| 06:30 ET |
Medarex to Host Conference Call Today to Discuss Bristol-Myers Squibb Development and Commercialization Collaboration for MDX-010
|
|
Oct 19, 04
|
| 16:02 ET |
Medarex to Present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference
|
|
Oct 12, 04
|
| 06:01 ET |
Medarex Announces Presentations on UltiMAb(TM) Antibodies at the 68th Annual Scientific Meeting of the American College of Rheumatology
|
|
Oct 06, 04
|
| 06:00 ET |
Medarex Announces MDX-060 Receives Orphan Drug Designation for Treatment of Hodgkin's Disease
|
|
Oct 05, 04
|
| 06:00 ET |
Medarex Receives FDA Fast Track Designation for MDX-010 Treatment of Metastatic Melanoma
|
|
Oct 04, 04
|
| 06:00 ET |
Medarex Receives Two NIH Grants for Development of Fully Human Antibody Against Anthrax
|
|
Oct 01, 04
|
| 06:00 ET |
Medarex Announces Presentations at Infectious Diseases Society of America Annual Meeting
|
|
Sep 29, 04
|
| 06:00 ET |
Massachusetts Biologic Laboratories and Medarex Announce Phase I Clinical Trial of a Novel Fully Human Antibody for the Treatment of Hospital Acquired Diarrhea
|
|
Sep 28, 04
|
| 16:02 ET |
Medarex Commences Enrollment in Phase III Clinical Trial for MDX-010 in Metastatic Melanoma
|
|
Sep 22, 04
|
| 16:00 ET |
Medarex to Present at the UBS Global Life Sciences Conference
|
|
Sep 20, 04
|
| 06:30 ET |
Medarex to Host Conference Call Today to Discuss Alliance with Pfizer
|
|
| 06:00 ET |
Medarex Announces Major Antibody Strategic Alliance with Pfizer
|
|
Sep 16, 04
|
| 06:00 ET |
Medarex and diaDexus Expand Collaboration for Development of Fully Human Antibody Therapeutics for the Treatment of Cancer
|
|
Sep 14, 04
|
| 06:00 ET |
Medarex Announces Commencement of Phase I Clinical Trial by Lilly for Therapeutic Antibody
|
|
Sep 13, 04
|
| 06:00 ET |
Medarex and Cell Genesys Initiate Phase I Clinical Trial of MDX-010 in Combination with GVAX(R) Prostate Cancer Vaccine
|
|
Sep 09, 04
|
| 16:00 ET |
Medarex to Present at the Bear Stearns 17th Annual Health Care Conference
|
|
Sep 07, 04
|
| 16:45 ET |
Medarex to Present at the BioCentury and Thomson Financial Newsmakers in the Biotech Industry Conference
|
|
Aug 23, 04
|
| 06:00 ET |
Medarex Announces Special Protocol Assessment Agreement with FDA to Initiate Phase III Clinical Trial for MDX-010 in Metastatic Melanoma
|
|
Aug 09, 04
|
| 08:02 ET |
Medarex Announces 2004 Second Quarter Financial Results
|
|
Aug 03, 04
|
| 16:14 ET |
Medarex to Announce Second Quarter Results on August 9, 2004
|
|
Jun 25, 04
|
| 06:00 ET |
Medarex Announces Purchase of Ability Biomedical Corporation
|
|
Jun 23, 04
|
| 06:00 ET |
Medarex Initiates Phase II Clinical Trial with MDX-070 in Prostate Cancer
|
|
Jun 14, 04
|
| 12:00 ET |
Medarex to Present at the Third Annual Needham Biotechnology Conference
|
|
Jun 09, 04
|
| 08:02 ET |
Medarex Announces MDX-010 Receives Orphan Drug Designation
|
|
| 06:00 ET |
Medarex Announces Promising Phase II Results with MDX-060 in Hodgkin's Disease
|
|
Jun 07, 04
|
| 09:02 ET |
Medarex Announces Positive Data with MDX-010 and Dacarbazine Combination in Metastatic Melanoma Phase II Study
|
|
Jun 03, 04
|
| 11:00 ET |
Medarex to Present at the 25th Annual Goldman Sachs Healthcare Conference
|
|
| 09:01 ET |
Medarex Announces Upcoming Presentations at American Society of Clinical Oncology Meeting
|
|
May 27, 04
|
| 06:00 ET |
Medarex, Inc. to Redeem All Outstanding 4.50% Convertible Subordinated Notes Due 2006
|
|
May 06, 04
|
| 16:01 ET |
Medarex Announces 2004 First Quarter Financial Results
|
|
Apr 28, 04
|
| 07:40 ET |
Medarex Announces Pricing of $150 Million of 2.25% Convertible Senior Note Offering to Refinance 4.50% Convertible Subordinated Notes Due 2006
|
|
Apr 26, 04
|
| 08:34 ET |
SARS Antibody Sent to China for Preclinical Testing
|
|
| 07:32 ET |
Medarex Announces Proposed Convertible Senior Note Offering to Refinance 4.50% Convertible Subordinated Notes Due 2006
|
|
Feb 26, 04
|
| 16:00 ET |
Medarex Announces 2003 Fourth Quarter and Year-End Financial Results
|
|
Feb 23, 04
|
| 06:00 ET |
Medarex to Announce 2003 Fourth Quarter and Year-End Financial Results on February 26, 2004
|
|
Feb 19, 04
|
| 06:01 ET |
Medarex to Present at the 6th Annual BIO CEO and Investor Conference
|
|
Jan 20, 04
|
| 06:00 ET |
Medarex and Xerion Announce Antibody Deal
|
|
Jan 07, 04
|
| 06:00 ET |
Medarex to Present at the 22nd Annual JPMorgan Healthcare Conference
|
|
Dec 22, 03
|
| 06:01 ET |
Sixteenth Medarex Antibody Enters Clinical Development
|
|
Dec 18, 03
|
| 16:02 ET |
Medarex and Cyto Pulse Sciences Announce Research and License Agreement
|
|
| 08:01 ET |
Medarex Announces Commencement of Phase I Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis by FibroGen
|
|
Dec 11, 03
|
| 06:00 ET |
Medarex Announces Commencement of Phase I Clinical Trials by Centocor of Anti-Angiogenesis Antibody, CNTO 95
|
|
Dec 10, 03
|
| 16:00 ET |
Medarex Hosting R&D Day in New York City Tomorrow
|
|
Dec 09, 03
|
| 06:00 ET |
Medarex Announces Complete and Partial Responses Observed in Phase I/II Clinical Study of MDX-060 at ASH Meeting
|
|
Dec 02, 03
|
| 06:00 ET |
Medarex to Webcast its 2003 R&D Day Program
|
|
Nov 24, 03
|
| 06:01 ET |
Medarex Announces Phase I/II Clinical Trial Development of MDX-214 for The Treatment of EGF-R Overexpressing Cancers
|
|
Nov 10, 03
|
| 16:00 ET |
Medarex Announces 2003 Third Quarter Financial Results
|
|
Nov 07, 03
|
| 06:00 ET |
Medarex to Present at CSFB HealthCare Conference
|
|
Nov 05, 03
|
| 16:03 ET |
Medarex Announces MDX-010 Presentations at the American Society of Hematology Meeting
|
|
| 06:13 ET |
Medarex Announces MDX-060 Presentation at the American Society of Hematology Meeting
|
|
Nov 04, 03
|
| 06:00 ET |
Medarex Announces Achievement of Milestone in Agreement with Amgen
|
|
Oct 30, 03
|
| 06:01 ET |
Medarex and Avalon Announce Antibody Deal
|
|
Oct 17, 03
|
| 06:02 ET |
Medarex Fully Human Anti-Anthrax Antibody Protects and Treats Anthrax Infection in Animal Model
|
|
Oct 16, 03
|
| 16:20 ET |
BioWa and Medarex Announce Licensing of BioWa's Potelligent(TM) Technology
|
|
| 16:15 ET |
Diversa and Medarex Form Strategic Partnership for Antibody Engineering
|
|
Oct 09, 03
|
| 11:01 ET |
Researchers Neutralize SARS Virus in Lab Tests
|
|
Oct 02, 03
|
| 06:00 ET |
Medarex and Trillium Therapeutics Announce Collaboration to Develop Fully Human Antibody Therapeutics
|
|
Sep 22, 03
|
| 06:00 ET |
Medarex to Present at the UBS Global Life Sciences Conference
|
|
Sep 08, 03
|
| 06:01 ET |
Medarex Initiates Phase II Clinical Trial of MDX-010 in Breast Cancer
|
|
Sep 03, 03
|
| 06:00 ET |
Medarex to Present at the Bear Stearns 16th Annual Health Care Conference
|
|
Aug 12, 03
|
| 16:00 ET |
Medarex Announces 2003 Second Quarter Financial Results
|
|
Jul 28, 03
|
| 06:00 ET |
Medarex Appoints Steven A. Fischkoff, M.D. as Vice President, Clinical Science
|
|
Jul 22, 03
|
| 09:12 ET |
Medarex Announces Exercise of Initial Purchasers' Additional $25 Million of Convertible Senior Note Offering
|
|
Jul 18, 03
|
| 08:30 ET |
Medarex Announces Pricing of $100 Million Convertible Senior Note Offering
|
|
Jul 17, 03
|
| 07:12 ET |
Medarex Announces Proposed Convertible Senior Note Offering
|
|
Jun 25, 03
|
| 06:00 ET |
Anti-Cancer Responses in Metastatic Melanoma Patients Linked to Immune Activation by MDX-010 Published in the `Proceedings of the National Academy of Sciences' (PNAS)
|
|
Jun 11, 03
|
| 06:00 ET |
Medarex Initiates Phase I Clinical Trial of MDX-010 in HIV
|
|
Jun 09, 03
|
| 06:00 ET |
Medarex to Present at the 24th Annual Goldman Sachs Healthcare Conference
|
|
Jun 03, 03
|
| 10:33 ET |
Medarex Announces June 4th Webcast of MDX-010 Clinical Results Following ASCO Conference
|
|
May 30, 03
|
| 14:30 ET |
Medarex Announces Upcoming MDX-010 Presentations at American Society of Clinical Oncology Meeting
|
|
May 28, 03
|
| 06:00 ET |
Medarex Fully Human Antibody Demonstrates Activity Against Anthrax in Animal Model
|
|
May 15, 03
|
| 06:01 ET |
Medarex and Amrad Announce Agreement to Develop Therapeutic Antibodies
|
|
May 08, 03
|
| 16:05 ET |
Medarex Announces 2003 First Quarter Financial Results
|
|
May 07, 03
|
| 06:00 ET |
Medarex Invited to Testify on the Role of Fully Human Antibodies in Treating SARS
|
|
May 06, 03
|
| 06:01 ET |
Medarex Announces Commencement of Phase I Clinical Trials by Novartis of a Second UltiMAb Antibody
|
|
Apr 25, 03
|
| 07:21 ET |
Potential SARS Treatment to be Developed by Medarex and Massachusetts Biologic Laboratories
|
|
Apr 22, 03
|
| 06:00 ET |
Diatos and Medarex Announce Cancer Product Licensing Agreement
|
|
Apr 16, 03
|
| 06:00 ET |
Medarex Announces Antibody Development Partnership With Pfizer
|
|
Apr 08, 03
|
| 12:05 ET |
Medarex Antibody is the Subject of Clinical Data Published in the Proceedings of the National Academy of Sciences
|
|
Mar 19, 03
|
| 06:00 ET |
PRIMABioMed Subsidiary and Medarex Announce Commercial Alliance to Develop Cancer Antibodies
|
|
Mar 18, 03
|
| 16:09 ET |
Medarex Announces 2002 Fourth Quarter and Year-End Financial Results
|
|
Mar 07, 03
|
| 11:00 ET |
Medarex to Announce 2002 Fourth Quarter and Year-End Financial Results on March 18, 2003
|
|
Feb 27, 03
|
| 06:00 ET |
Medarex and Ferric Technologies Announce Agreement to Develop Therapeutic Antibodies
|
|
Feb 25, 03
|
| 16:00 ET |
Medarex to Present at the BIO CEO and Investor 2003 Conference
|
|
Jan 29, 03
|
| 06:00 ET |
Medarex and diaDexus Form Collaboration for the Development of Fully Human Antibody Therapeutics
|
|
Jan 27, 03
|
| 06:04 ET |
Medarex to Present at The US Bancorp Piper Jaffray Health Care Conference
|
|
Jan 20, 03
|
| 06:00 ET |
Medarex and Abbott Announce Collaboration to Develop Therapeutic Antibodies
|
|
Jan 07, 03
|
| 06:01 ET |
Medarex and Ability Biomedical Announce Alliance to Develop Fully Human Antibody Therapeutics
|
|
Jan 06, 03
|
| 16:30 ET |
Medarex Announces Filing of Investigational New Drug Application for MDX-070; Fully Human Anti-PSMA Antibody Candidate for Prostate Cancer
|
|
Jan 02, 03
|
| 16:00 ET |
Medarex to Present at the 21st Annual JPMorgan H&Q Healthcare Conference
|
|